EssilorLuxottica among the strongest gainers in the CAC 40, +24% in one month
EssilorLuxottica is among the best-performing stocks on the Paris index at midday, while the share price remains almost stable. The stock extends a sharp recovery, after a more volatile move over the last few days.
A 24% monthly gain leaves the stock above its three moving averages
The stock gains 1.26% to €184.65, the third-best performance in the CAC 40 behind Hermès and Thales, while the index rises 0.1%.
Over one month, the stock is up 24.18%, a rebound that has been under way since the publication of quarterly sales on October 20. The price is above its MM20 (a gap of 1.64%), its MM200 (2.66%) and its MM50 (15.18%).
The 4.72% decline over seven days does not call this pattern into question: the stock has just reclaimed its MM200 at €179.86, which it had regained after trading below it for a long time. The RSI at 60 remains neutral, far from overbought territory.
Quarterly sales driven by direct sales and myopia management
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
At the publication on October 20, the group reported third-quarter revenue of €7,486 million, up 7.2% at constant exchange rates.
Myopia management solutions grew 24% over nine months, and the direct-to-consumer segment rose 10.6% in the third quarter, with like-for-like store sales up 6.8%.
On October 23, S&P also raised the group's long-term credit rating to A+, with a stable outlook. On the chart, resistance at €193.80 is the next level to break, while support sits at €143.
SectorDispositifs médicaux et optique›Optique / lunetterie
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 9M 2026
Key reported figures
Revenue: 22 304 millions d'euros
Quarterly revenue: 22 304 millions d'euros
Revenue growth: 6,8 %
Opportunities identified
Le portefeuille des solutions de gestion de la myopie a progressé de +24 % sur les neuf premiers mois
Les activités traditionnelles (Eyecare & Medtech) ont progressé à un rythme supérieur à +6 %, tant au T3 que sur les neuf premiers mois
Segment Direct to Consumer en hausse de +10,6 % au T3, ventes à magasins comparables à +6,8 %
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.